Latest Videos
What is the additional clinical value of using a hybrid capture-based NGS platform? Can you discuss in terms of false-negativity and sensitivity analyses?
What is the rationale for using a validated genomic profiling platform that uses high sensitivity, hybrid capture-based NGS methodology to assess molecular drivers in solid tumors?
Can you bring comprehensive genomic profiling down to the oncologist-cancer patient level and explain what a FoundationOne Report looks like, what information it contains, how long it takes to generate a report and what the translational ...
What advances in therapeutic targeting with NGS comprehensive genomic profiling and multiplex testing have we witnessed in patients with NSCLC?
What is the unique status of hybrid capture NGS within the context of molecular target-driven therapy for solid tumors?
How do you approach drug selection decisions when you encounter multiple actionable targets?
How do you approach drug selection decisions when you encounter multiple actionable targets?
Do mutational targets in solid tumors change over time, and does this justify multiple biopsies and repeat NGS-based profiling in the case of progressive disease to identify new drivers that may have treatment implications?
At what stage of a cancer’s presentation or evolution is the oncologist advised to deploy genomic profiling to inform clinical decision-making and therapeutic choices aligned with specific alterations and mutations?
How do we curate the results of NGS-based genomic profiles? In particular, how do we prioritize subsidiary molecular markers, especially when there are multiple drivers identified, and determine their level of actionability? Is there a ...
In addition to the molecular alterations identified by the NGS, what additional information is provided by these reports that is critical to drug selection?
How do the different technology platforms —from hot spot panels to FoundationOne—for characterizing molecular drivers differ; and why do NGS-based hybrid capture platforms offer the most reproducible and actionable results?
Can you share specific patient examples where molecular profiling has affected a clinical treatment decision and produced a favorable outcome?